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Background: Constitutive activation of the phosphoinositide 3-kinase/protein kinase
B survival signal transduction pathway influences the intrinsic chemoresistance of
cancer cells. This study evaluates the effect of LY294002, a pharmacologic inhibitor
of phosphoinositide 3-kinase, on the sensitivity of lung and esophageal cancer cells
to paclitaxel (Taxol) in vitro.
Materials and Methods: Cell viability and apoptosis of cancer cells treated with
paclitaxel  LY294002 combinations were quantitated by methyl-thiazol-diphenyl-
tetrazolium and terminal deoxynucleotidyltransferase-mediated dUTP nick-end la-
beling-based ApoBrdU assays, respectively. The effect of LY294002-mediated
phosphoinositide 3-kinase inhibition on protein kinase B (Akt) activation and
nuclear factor-B signaling was determined by Western blot analysis. Nuclear
factor-B transcription activity in cultured cancer cells either at baseline or after
treatments with LY294002 or BAY11-0782 (a pharmacologic inhibitor of nuclear
factor-B) was determined by the nuclear factor-B-Luciferase reporter system.
Results: A 4- to more than 20-fold reduction of paclitaxel IC50 values was observed
in cancer cells treated with paclitaxel  LY294002 combinations. This was paral-
leled with synergistic induction of apoptosis. LY294002 treatment caused a signif-
icant dose-dependent inhibition of protein kinase B (Akt) activation and suppression
of nuclear factor-B transcriptional activity that was accompanied by elevation of
IB, the intrinsic inhibitor of nuclear factor-B, and concomitant reduction of
nuclear factor-B–regulated antiapoptotic proteins cIAP1, cIAP2, and BclXL. Di-
rect inhibition of nuclear factor-B activity by BAY11-0782 also resulted in
profound enhancement of paclitaxel sensitivity and paclitaxel-mediated induction of
apoptosis in lung and esophageal cancer cells.
Conclusion: LY294002-mediated inhibition of the phosphoinositide 3-kinase/pro-
tein kinase B-dependent survival pathway with secondary suppression of nuclear
factor-B transcriptional activity was associated with enhancement of paclitaxel
cytotoxicity in lung and esophageal cancer cells. Direct inhibition of nuclear
factor-B by BAY11-0782 also sensitized these cancer cells to paclitaxel, indicating
that nuclear factor-B may be the crucial intermediary step connecting phospho-
inositide 3-kinase/protein kinase B (Akt) to the intrinsic susceptibility of cancer
cells to chemotherapeutic agents.
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Malignant tumors of epithelial origin,including those originating from thelung or the esophagus, are generallyrefractory to current cytotoxic che-motherapeutic agents. This poses amajor therapeutic dilemma for the
majority of patients with lung or esophageal cancers be-
cause they frequently present with locally advanced or
metastatic disease for which chemotherapy or radiation is
the only treatment option. Chemotherapy, at best, provides
symptomatic relief of cancer symptoms and improves qual-
ity of life with marginal prolongation of survival for a few
months in patients with stage IV lung or esophageal can-
cers.1,2
The molecular basis of chemoresistance in malignant
cells is incompletely understood and seems to involve com-
plex interactions of both genetic and epigenetic factors.
Detailed molecular analysis of growth factor signal trans-
duction pathways, exemplified by studies of members of the
epidermal growth factor receptor (EGFR) superfamily, that
is, HER2/neu or EGFR, has shown their roles in the process
intrinsic chemoresistance of cancer cells.2 Of significant
importance is the identification of the intracellular signaling
pathways governed by phosphoinositide 3-kinase (PI3K) as
the cell survival pathways and their roles in protecting cells
against cytotoxic stress.3 PI3K activation is initiated, and
thus controlled, by growth factors through activation of
their cognate membrane receptors. Schematic presentation
of growth factor–induced activation of PI3K and its down-
stream targets is shown in Figure 1. Phosphorylation of the
growth factor receptors subsequent to binding of growth
factors allows recruitment of adaptor molecules such as
SOS and Grb2. PI3K translocates to the membrane and is
activated by either direct binding to phosphorylated recep-
tors or adaptor molecules. PI3K phosphorylates the cell
membrane phosphatidylinositol lipids to form phosphatidyl-
inositol-3,4,5-triphosphate (PIP3). PIP3 attracts protein ki-
nase B (Akt) and 3' phosphoinositide-dependent kinase 1
(PDK1) to the cell membrane and brings them to physical
proximity where Akt is phosphorylated and activated by
PDK1. Activated Akt in turn phosphorylates and modulates
the function of a myriad of cellular proteins resulting in an
antiapoptotic milieu that enables activated cells to survive
cytotoxic stress.3,4 Functional inhibition of PI3K or Akt in
malignant cells should decrease their survival capacity and
increase their susceptibility to the cytotoxic effects of che-
motherapeutic agents.4-9
This study determined whether blocking PI3K function
by the pharmacologic agent LY294002 (LY) could inhibit
Akt activation and sensitize cultured lung and esophageal
cancer cells to the cytotoxic effect of paclitaxel (Taxol).
Because Akt signaling is directly linked to the survival
transcription factor nuclear factor (NF)-B through the IK/
IB complex, we questioned whether LY-mediated PI3K
inhibition also suppresses the transcription activity of NF-
B, which may in turn act as the intermediary step of the
chemosensitization effect of this compound. To directly
address this issue, intrinsic cellular NF-B activity of cul-
tured lung and esophageal cancer cells was directly inhib-
ited by the IK inhibitor BAY11-7082 (BAY),10 and treated




Non–small cell lung cancer (NSCLC) cells H460, H226, and H322
and esophageal cancer cells SKGT5, HCE4, and TE2 were main-
tained in Roswell Park Memorial Institute (RPMI) 1460 culture
medium supplemented with streptomycin (100 g/mL) and peni-
cillin (100 U/mL), glutamine (2 mmol/L), and 10% (vol/vol) fetal
calf serum (complete medium). LY and BAY were purchased from
Sigma (St Louis, Mo) and Alexis Corp (San Diego, Calif), respec-
tively. They were dissolved in dimethyl sulfoxide as 10-mmol/L
stocks and stored at 80°C. Plasmid containing the Luciferase
gene under the control of a promoter containing the NF-B bind-
ing consensus sequences (NF-B-Luc) (BD Biosciences Clontech,
Palo Alto, Calif) and plasmid containing the -galactosidase gene
under the control of the Roux sarcoma virus promoter (RSV-LacZ)
were purchased from Clontech (Palo Alto, Calif). Bacteria stocks
containing the plasmids were amplified in LB broth under ampi-
cillin selection, and plasmids were isolated using the CsCl tech-
nique. Methyl-thiazol-diphenyl-tetrazolium (MTT) was obtained
from Sigma. Paclitaxel was purchased from Bristol-Myers-Squibb
(Lawrenceville, NJ) through the pharmacy of the National Insti-
tutes of Health Clinical Center. Luciferase assay kits were obtained
from Promega (Madison, Wis).
Cell Proliferation and Apoptosis Assays
Cancer cells were seeded in 96-well microtiter plates at predeter-
mined cell densities (5-10  103 cells/well) for optimal results.
After an overnight incubation to allow cells to attach to the bottom
of the wells, the culture medium was removed and cells were
treated with paclitaxel (16-4000 nmol/L in serum-free RPMI me-
dium) for 90 minutes. Cells were recultured in complete medium
after paclitaxel treatment. Twelve hours later, they were treated
with LY (10, 20, or 40 mol/L) or BAY (10, 20, or 30 mol/L).
Cell viability was evaluated by MTT assay at 72 hours after the
onset of paclitaxel treatment. The sensitivity of tumor cells to
paclitaxel (after paclitaxel treatment alone or in combination with
LY or BAY) was determined by estimating the paclitaxel IC50
values (paclitaxel doses that induced 50% growth inhibition) from
the dose-response curves. Appropriate corrections were made to
account for the mild growth inhibitory effect of LY or BAY when
calculating paclitaxel IC50 values of cells treated with the drug
combination. For apoptosis assays, NSCLC or esophageal cancer
cells were seeded in 6-well tissue culture plates at 3 105 cells per
well. They were then treated with the sequential paclitaxel  LY
or paclitaxel  BAY combinations. Cells were harvested 60 hours
after the onset of paclitaxel treatment, and apoptosis was quanti-
tated using the terminal deoxynucleotide transferase-mediated
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dUTP nick-end labeling (TUNEL)-based ApoBrdU assay (BD
Pharmingen, San Diego, Calif) according to the protocol provided
by the manufacturer. To determine the growth inhibitory effect of
LY, cells were similarly seeded in 96-well plates in complete
medium and then continuously exposed to increasing concentra-
tions of LY (5-80 mol/L) for 60 hours, and cell viability was
quantitated by MTT assay. The effect of LY treatment on cell-
cycle progression of cancer cells treated with LY (10 or 40
mol/L) for either 24 hours or 48 hours was evaluated by pro-
pidium iodide staining, and flow cytometry was used to evaluate
the effect of LY treatment (10 mol/L or 40 mol/L for either 24
or 48 hours) on cell-cycle progression in cancer cells.
NF-B Transcription Activity Assay
Cultured cancer cells were transiently transfected with NF-B-Luc
or RSV-LacZ plasmids using FuGene (Roche Diagnostics, India-
napolis, Ind) according to the protocol provided by the manufac-
turer. Luciferase activity, as measured by commercially available
kits and a lucinometer (Perkin Elmer-Wallac, Westbury, NY)
(normalized for protein content of cell lysates and the -galacto-
sidase activity serving as internal control for transduction effi-
ciency), directly correlates with the levels of NF-B transcription
activity. Transfected cells were treated with LY (10, 20, or 40
mol/L) for 18 hours, and Luciferase or -galactosidase activities
and cellular protein content bicinchoninic acid technique, Pierce
Biotechnology, Inc, Rockford, Ill) were measured. Normalized
Luciferase activity of treated cells was then expressed as percent-
ages of activity of untreated control cells.
Western Blots
NSCLC or esophageal cancer cells were treated with LY (10, 20,
or 40 mol/L) for 18 hours and harvested in Laemmli buffer. Cell
lysates were immunoblotted using the standard Western blot tech-
nique with monoclonal antibodies recognizing phosphorylated and
total Akt (Cell Signaling Technology, Beverly, Mass), IB,
cIAP-1, cIAP-2 (R&D, Minneapolis, Minn), and BclXL (Upstate
Biotechnology, Lake Placid, NY). Blots were also probed for
-actin (Oncogene Research Product, Cambridge, Mass) to verify
equal loadings of proteins.
Data Analysis
Data are expressed as mean and SD for at least 3 independent
experiments that yielded similar results. The student t test was used
for statistical analysis.
Results
LY-Mediated Growth Inhibition by Induction of Cell-
Cycle Arrest at the G0/G1 Checkpoint
Continuous exposure of NSCLC and esophageal cancer
cells to LY resulted in a significant dose-dependent reduc-
tion of the levels of phosphorylated Akt (without altering
Figure 1. Downstream signaling of activated Akt. Binding of growth factors to their cognate receptors results in
receptor phosphorylation, recruitment of multiple adaptor proteins (SOS and Grb2), activation of PI3K, and
generation of PIP3 in the plasma membrane. PIP3 provides docking sites for proteins containing the Pleckstrin
homology domain (eg, Akt and PDK1) to accumulate at the sites of PI3K activation. Proximity of Akt and PDK results
in phosphorylation and activation of Akt. Activated Akt in turn phosphorylates and modulates functions of a myriad
of cellular proteins, creating an antiapoptotic milieu and enhanced cell-survival capacity. NF, Nuclear factor; PIP3 ,
phosphatidylinositol-3,4,5-triphosphate.
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the total Akt levels) that was correlated with inhibition of
cell proliferation in vitro (Figure 2, A and B). Cell-cycle
analysis indicated that LY treatment caused a dose-depen-
dent and treatment duration-dependent accumulation of
cells at the G0/G1 phase with a corresponding reduction of
cells in the S and G2/M phases of the cell cycle, compatible
with cell arrest at the G1/S checkpoint as shown in Figure 3
for H460 NSCLC and TE2 esophageal cancer cells. Similar
findings were also noted with other cultured NSCLC and
esophageal cancer cell lines (data not shown).
LY-Mediated Suppression of NF-B Activity in
NSCLC and Esophageal Cancer Cells
Activated (phosphorylated) Akt stimulates the NF-B by
degrading IB (the natural inhibitor of NF-B) and enhanc-
ing the transcriptional activity of the p65/RelA subunit of
the NF-B complex.10-14 Active NF-B, in turn, up-regu-
lates the expression of antiapoptotic proteins cIAP1, cIAP2,
and BclXL. Further analysis of the effect of LY treatment
on the levels of phosphorylated Akt, and those linking to the
NF-B pathway (IB, cIAP1, cIAP2, and BclXL) in repre-
sentative NSCLC cells H460 and H322, and esophageal
cancer cells SKGT5 and TE2 is shown in Figure 4, A. In
addition to suppressing constitutive activation of Akt (re-
duction of phosphorylated Akt), LY treatment also resulted
in dose-dependent elevation of IB levels and reduction of
NF-B–dependent antiapoptotic proteins cIAP1, cIAP2 (ei-
ther one or both), and BclXL.
Transcriptional activity of NF-B in tumor cells was
quantitatively evaluated by using the reporter plasmid NF-
B-Luc. Preliminary experiments were performed using
H460 and H322 cells to define the kinetics of LY-mediated
inhibition of NF-B activity. Treating these cells that were
transiently transfected with the reporter plasmid with LY
(10, 20, and 40 mol/L) resulted in significant treatment
duration-dependent and dose-dependent inhibition of
NF-B transcriptional activity. NF-B activity started to
decrease as early as 6 hours after the initiation of LY
treatment and became profound after 18 hours of exposure
to this PI3K inhibitor (data not shown). In subsequent
experiments, NF-B activity of cells treated with LY was
evaluated after 18 hours of drug treatment. LY caused
significant dose-dependent reduction of NF-B transcrip-
tional activity in all 6 cell lines evaluated. The magnitude of
inhibition of NF-B activity ranged from 20% to 40% at 10
mol/L of LY to as high as 60% to 80% at 40 mol/L of
LY (Figure 4, B).
Figure 2. A, Western blot analysis of LY-mediated dose-dependent suppression of Akt phosphorylation in NSCLC
and esophageal cancer cell lines in vitro. B, Dose-dependent inhibition of cell proliferation by LY in NSCLC and
esophageal cancer cells. Cells were treated with increasing concentrations of LY for 60 hours, and viable cells
were quantitated by MTT assay. Data are presented as mean  SD of 3 independent experiments.
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Enhancement of Paclitaxel Cytotoxicity by LY in
NSCLC and Esophageal Cancer Cells In Vitro
Treating NSCLC or esophageal cancer cells with paclitaxel
for 90 minutes resulted in significant dose-dependent inhi-
bition of cell proliferation in vitro. Intrinsic cellular sensi-
tivity to paclitaxel cytotoxicity varied between cell lines
with paclitaxel IC50 values ranging from 210 to 940 nmol/L.
Subsequent exposure of paclitaxel-treated cells to LY
(10-40 mol/L) resulted in further reduction of cell viabil-
ity, the magnitude of which exceeded the mild growth-
inhibitory effect of LY alone, particularly at low concen-
trations of paclitaxel (16-250 nmol/L), suggestive of a
synergistic drug combination effect (Figure 5). This was
further demonstrated by estimating paclitaxel IC50 values of
cells treated with paclitaxel  LY combinations. There was
a 4- to more than 20-fold reduction of paclitaxel IC50 values
in cells treated with paclitaxel  LY compared with the
values of cells treated with paclitaxel alone (Figure 5).
Paclitaxel treatment (50-500 nmol/L) was associated with
activation of the PI3K/Akt pathway as indicated by elevated
phosphorylated Akt levels that were profoundly suppressed
by subsequent exposure to the PI3K inhibitor LY (40
mol/L) (Figure 6, A). Such elevations of phosphorylated
Akt levels were paralleled with increased NF-B transcrip-
tional activity that was also suppressed by LY treatment
(Figure 6, B). More important, cells treated with this drug
combination were observed to undergo significant apoptosis
even when treated at concentrations of paclitaxel or LY that
induced only minor degrees of programmed cell death as
detected by the TUNEL-based ApoBrdU assay (Figure 6,
C).
BAY and BAY-Mediated Enhancement of Paclitaxel-
Induced Apoptosis
LY-mediated enhancement of paclitaxel sensitivity was par-
alleled by its ability to down-regulate NF-B activity. Sub-
sequent experiments were performed to investigate the role
of NF-B on paclitaxel sensitivity in cultured lung and
esophageal cancer cells. Direct inhibition of NF-B was
achieved by BAY, a potent inhibitor of IK. Figure 7, A
indicates significant dose-dependent inhibition of NF-B
transcription activity by BAY in lung and esophageal cancer
Figure 3. Dose- and time-dependent LY-mediated cell-cycle arrest at G0/G1 checkpoint in H460 NSCLC and TE2
esophageal cancer cells in vitro. Cell-cycle analysis was performed using propidium iodide staining and flow
cytometry.
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cell lines in vitro. The magnitude of inhibition varied be-
tween cell lines, ranging from 40% to 90% at 20 mol/L of
BAY. Direct inhibition of NF-B by BAY in cells treated
with sublethal doses of paclitaxel resulted in massive
induction of apoptosis, matching (as in H322 and TE2
cells) or even exceeding (as in H460 and SKGT5 cells)
the degrees of apoptosis induced by paclitaxel  LY
(Figure 7, B).
Discussion
PI3K has recently been identified as a critical intracellular
component downstream of growth factor receptor signaling.
Aberrant PI3K function has been implicated in diverse
pathologic conditions including diabetes mellitus and can-
cer.3 Activation of PI3K is a function of growth factor-
mediated activation and phosphorylation of its membrane
receptor and the oncoprotein K-Ras.3 Overexpression of
growth factors (members of the EGFR superfamily, insulin-
like growth factor receptors, and receptors for hepatocyte
growth factor/scatter factor) or mutation of K-Ras is very
common in cancers, including those of the lung and the
esophagus.2 Cancer cells with high levels of PI3K activation
exhibit enhanced resistance to cytotoxic stress induced by
serum deprivation or exposure to chemotherapeutic agents.3
PI3K transmits its signal through activation of Akt, which in
turn phosphorylates and thereby modulates the function of
numerous target proteins, including IK and NF-B p65/
RelA subunit (to activate the NF-B pathway),11-15 caspase
9 and Bad (to inhibit proapoptotic activity),16,17 and p21 or
p27 (to suppress cell-cycle regulation activity).18,19 Because
of their strategic roles in modulating growth and survival
signal transduction cascades, PI3K and Akt are attractive
molecular targets for cancer therapy. The availability of
pharmacologic inhibitors of PI3K such as LY or Wortman-
nin greatly facilitates the molecular analysis of pathophys-
iologic roles of PI3K/Akt signaling in cancer cells, partic-
ularly with respect to its influence on chemosensitivity and
resistance.
Figure 4. A, LY-mediated dose-dependent reduction of phosphorylated Akt levels in H322 and H460 NSCLC cells
and SKGT5 and TE2 esophageal cancer cells was paralleled with increase of IB levels and reduced expression
of NF-B– dependent antiapoptotic proteins cIAP1, cIAP2, and BclXL. B, LY-mediated dose-dependent suppression
of intrinsic NF-B activity in cultured NSCLC and esophageal cancer cells as determined by the NF-B-Luciferase
reporter system. Luciferase activity in LY-treated cells was expressed as percentages of activity of untreated
control cells. Data are expressed as mean  SD of 3 independent experiments (*P < .001-P  .004 vs controls).
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Our data indicate that cultured lung and esophageal can-
cer cells constitutively expressed high levels of phosphor-
ylated (activated) Akt and that LY-mediated profound re-
duction of activated Akt in these cells coincided with potent
sensitization of treated cells to paclitaxel, in keeping with
previous observations.5,8 However, evidence was lacking
regarding the molecular mechanism of this LY-mediated
salutary effect. Inhibition of PI3K/Akt signaling modulates
many distinct cellular proteins, all of which participate in
the apoptotic machinery. Any one of them, alone or in
combination with others, may be responsible for the che-
mosensitization aspect of PI3K/Akt inhibition. Of all the
downstream targets of Akt, the NF-B pathway deserves
further investigation as an intermediary step mediating sur-
vival and chemoresistance function for PI3K/Akt. High
levels of NF-B activity have been linked to chemoresis-
tance in breast cancer, which could be reversed by inhibition
of NF-B through overexpression of IB gene by genetic
manipulation or pharmacologic inhibitors.20,21 Our data in-
dicate a correlation between LY-mediated suppression of
NF-B transcription activity plus NF-B-regulated anti-
apoptotic proteins and LY-dependent sensitization to pacli-
taxel. Our data also indicate that direct inhibition of NF-B
by BAY synergistically induced profound apoptosis in pa-
clitaxel-treated lung and esophageal cancer cells. These
circumstantial pieces of evidence indicate that LY-mediated
suppression of NF-B activity actually participates in the
process of chemosensitization mediated by PI3K inhibition.
Confirmatory experiments using similar cell lines that are
genetically engineered to express constitutively activated
Figure 5. Supra-additive enhancement of cytotoxicity mediated by the Taxol  LY combinations. Although LY
induced mild reduction of cell proliferation, exposure of Taxol-treated cells to LY resulted in further reduction of
cell viability that exceeded the growth-inhibitory effect mediated by LY. Cultured cancer cells were treated with
varying doses of Taxol for 90 minutes, followed by exposure to LY (10, 20, or 40 mol/L) 12 hours later. Viable cells
were quantitated by MTT assay 72 hours after the onset of Taxol treatment. Data are expressed as mean  SD of
4 independent experiments.
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PI3K and the dominant negative mutant of IK are in
progress to conclusively define the role of NF-B as the
intermediary step in the process of LY-mediated chemosen-
sitization in cancer cells relative to cultured primary normal
epithelia or fibroblasts.
Conclusion
Inhibition of the PI3K/Akt survival signal transduction
pathway enhances paclitaxel-mediated cytotoxicity in
cultured lung and esophageal cancer cells in vitro. The
NF-B pathway, which is down-regulated by the PI3K
Figure 6. Activation of Akt (increased phosphorylated Akt levels) (A) and significant elevation of NF-B transcrip-
tional activity (as determined by NF-B Luciferase reporter system) (B) in H322 NSCLC and TE2 esophageal cancer
cells treated with increasing concentrations of Taxol (50, 100, or 500 nmol/L) was totally suppressed by PI3K
inhibitor LY (40 mol/L). Mean SD; 3 independent experiments (*P .012 vs controls, #P < .001 vs Taxol-treated
cells). The combinations of Taxol and LY synergistically induced apoptosis in NSCLC and esophageal cancer cells
(C). Cells were sequentially treated with Taxol and LY for 60 hours before harvest and assayed for DNA
fragmentation of apoptosis using the TUNEL-based ApoBrdU technique. Data are expressed as mean  SD of 3
independent experiments (*P < .001-P  .007 of Taxol  LY vs Taxol alone or LY alone). TUNEL, Terminal
deoxynucleotide transferase-mediated dUTP nick-end labeling.
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inhibitor LY and inhibition of which enhances paclitaxel
sensitivity, seems to be a critical intermediary step
connecting PI3K/Akt with the cellular process of chemo-
sensitivity and resistance. The findings of this study
provide the rationale for further preclinical studies eval-
uating the potential efficacy of anticancer therapeutic
strategies targeting components of the PI3K/Akt signal-
ing pathway.
Figure 7. A, BAY, through direct inhibition of IK, also suppressed intrinsic NF-B activity in NSCLC and
esophageal cancer cells. Data are expressed as mean  SD of 4 independent experiments (*P < .001-P  .013 vs
controls). B, This was paralleled with an enhancement of the magnitude of apoptosis in cells treated with the Taxol
 BAY combination. Representative data of 3 independent experiments that yielded similar results are shown here.
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Discussion
Dr David A. Jones (Charlottesville, Va). Did you look at kappa
B transcriptional activation with Luciferase in one of your slides?
Was the control just no treatment at all or was the control actually
with paclitaxel?
Dr Nguyen. NF-B transcriptional activity was evaluated by
using NF-B-Luciferase reporter plasmid assays. The controls for
these assays were cells incubated in 10% fetal calf serum RPMI
without any drug treatment at all.
Dr Jones. So do you have any evidence that paclitaxel either
activated Akt or activates NF-B?
Dr Nguyen. As shown by the Western blot of phosphorylated
Akt in NSCLC and esophageal cancer cells treated with increasing
concentrations of paclitaxel, paclitaxel exposure resulted in a dose-
dependent increase in phosphorylated Akt levels without affecting
total Akt levels, and LY treatment abrogated this phosphorylated
Akt increase, indicating that there was activation of the Akt path-
way probably through the PI3K pathway. With regard to paclitaxel
effect on NF-B transcriptional activity, we had some preliminary
data and are in the process of substantiating the observations that
there was elevation of NF-B transcriptional activity after pacli-
taxel treatment.
Dr Jones. I think that is an important question. We have been
able to show that chemotherapy activates NF-B–dependent tran-
scription, and one of the mechanisms of chemoresistance is acti-
vating the cell survival pathway. But I didn’t know whether you
think paclitaxel actually activates Akt, being that it is upstream of
NF-B. Do you think Akt is activated by some type of cell
membrane receptor or a change in the redox status of the cell or do
you think that this is just true and unrelated, meaning chemother-
apy does not activate Akt?
Dr Nguyen. That is an interesting comment. The current focus
of our laboratory at the moment is to decipher the actual intracel-
lular signaling of PI3K/Akt and NF-B after paclitaxel treatment.
It is conceivable that as part of a stress response, there is up-
regulation of phenotypic expression or function of growth recep-
tors, notably EGFR, which provides the upstream signaling for the
PI3K/Akt axis after exposure to cytotoxic chemotherapeutics.
There are reports in the literature demonstrating that there was
activation of EGFR-mediated signaling after paclitaxel exposure,
and this formed the basis for combining paclitaxel with anti-EGFR
therapy strategies. I have no data on the role of oxygen free
radicals as a putative mechanism for NF-B activation or Akt
activation in paclitaxel-treated cells.
Dr Steven J. Mentzer (Boston, Mass). You just have cell
viability, you don’t have cell proliferation or cell cycle. What does
your inhibitor do to the cell cycle in these cell lines?
Dr Nguyen. In the full article, I have the diagram showing that
LY actually induces cell-cycle arrest at the G0/G1 checkpoint.
Dr Mentzer. So it isn’t just a population dynamics issue when
you are selecting?
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Dr Nguyen. No, I think it is more than just a perturbation of
cell cycle. I think it has something to do with cancer cells’ survival
response to stress.
Dr David H. Harpole, Jr (Durham, NC). Could you go back
to the slide with the graphs of paclitaxel showing the suppressor at
different doses? There was something that was a little confusing to
me.
If I look at the top panels, at the zero time point, it looks like
the fractured cell viability is actually decreased. Those lines are
almost parallel. So what I am trying to say is that by looking at
them myself, I can’t really see that there’s a difference in the
top, middle, and lower panels with respect to the paclitaxel kill,
if you normalize them all at zero time points to the same
baseline. Does that make sense? Because the 3 lines are parallel
to each other, I think what you are showing is the effect of
giving your agent, but I am not sure that it shows a dependence
on paclitaxel.
Dr Nguyen. Right. I do see what you mean. I had to normalize
LY-treated cells alone to calculate paclitaxel IC50 values (indica-
tive of paclitaxel effect in LY-treated cells with exclusion of LY
mild growth inhibitory effect). These graphs are not to scale, so
that’s why they look like that.
Dr Harpole. All right. That explains it. Because at first it didn’t
seem to make sense.
Dr Nguyen. Right. Because if I put the graphs to scale, it is
very hard to demonstrate the point. But once you normalize for that
and calculate out the paclitaxel IC50 values, there is a clear
enhancement of paclitaxel cytotoxicity by LY.
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